ReviewNature reviews. Urology2015
Imaging and evaluation of patients with high-risk prostate cancer.
Review in Nature reviews. Urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06071195 (All-in-One Prostate Cancer Staging with MRI), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
All-in-One Prostate Cancer Staging with MRI
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Has the Landscape of Immunotherapy for Prostate Cancer Changed? A Systematic Review and Post Hoc Analysis.American journal of men's healthPooled it
- Trial
- Predicting bone metastasis and high-grade Gleason scores in prostate cancer: a retrospective study integrating clinical features and magnetic resonance imaging radiomics.Translational andrology and urology · 2025Article
- Misdiagnosis of supraclavicular brachial plexus metastasis as cervical disc herniation: A lung cancer case report.The Journal of international medical research · 2025Article
- The diagnostic value of whole-body HYNIC-PSMA 11 -Tc [Annals of nuclear medicine · 2025Article
- [Frontiers in medicine · 2025Article
- Recommendations from Imaging, Oncology, and Radiology Organizations to Guide Management in Prostate Cancer: Summary of Current Recommendations.Radiology. Imaging cancer · 2025Review
- Emerging Role of Nuclear Medicine in Prostate Cancer: Current State and Future Perspectives.Cancers · 2023Review
- Article
- Current Opinion on the Use of Magnetic Resonance Imaging in Staging Prostate Cancer: A Narrative Review.Cancer management and research · 2022Review
- Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging.European radiology · 2019Article
- Patient-specific 3D printed and augmented reality kidney and prostate cancer models: impact on patient education.3D printing in medicine · 2019Article
- Article
- Cytoreductive radical prostatectomy in metastatic prostate cancer: Does it really make sense?World journal of urology · 2017Review
- Evaluation of sHLA-G levels in serum of patients with prostate cancer identify as a potential of tumor marker.Anatomy & cell biology · 2017Article
- Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.Oncotarget · 2016Review
- A urologist's perspective on prostate cancer imaging: past, present, and future.Abdominal radiology (New York) · 2016Article
- Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes.Theranostics · 2016Article
- Transcription Factor HBP1 Enhances Radiosensitivity by Inducing Apoptosis in Prostate Cancer Cell Lines.Analytical cellular pathology (Amsterdam) · 2016Article
- Combined analysis of CRMP4 methylation levels and CAPRA-S score predicts metastasis and outcomes in prostate cancer patients.Asian journal of andrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately 15% of men with newly diagnosed prostate cancer have high-risk disease. Imaging is critically important for the diagnosis and staging of these patients, and also for the selection of management. While established prostate cancer staging guidelines have increased the appropriate use of imaging, underuse for high-risk prostate cancer remains substantial. Several factors affect the utility of initial diagnostic imaging, including the variable definition of high-risk prostate cancer, variable guideline recommendations, poor accuracy of existing imaging tests, and the difficulty in validating imaging findings. Conventional imaging modalities, including CT and radionuclide bone scan, have been employed for local and metastatic staging, but their performance characteristics have generally been poor. Emerging modalities including multiparametricMRI, positron emission tomography (PET)-CT, and PET-MRI have shown increased diagnostic accuracy and could improve accuracy in staging patients with high-risk prostate cancer.
Indexed as
Identifiers
26481576What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.